Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)
This is an expanded access protocol designed to make Lucanix® available to subjects with advanced non-small cell lung cancer (NSCLC) who are not eligible for the Phase III Protocol, NR001-03. A total of 45 patients will be enrolled into the study.
Non-small Cell Lung Cancer
BIOLOGICAL: Lucanix® (belagenpumatucel-L)
The primary objective of this study is to increase the overall survival of the study subjects by providing expanded access to Lucanix. Overall survival and progression-free survivals will be compared with historical controls.

The secondary objectives of this study are:

* Evaluate the best overall tumor response.
* Evaluate progression-free survival (PFS).
* Evaluate treatment toxicity.